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S U M M A R Y
Background: Baseline age and combination antiretroviral therapy (cART) were examined as determi-
nants of CD4+ T-cell recovery during 6 months of tuberculosis (TB) therapy with/without cART. It was
determined whether this association was modiﬁed by patient sex and nutritional status.
Methods: This longitudinal analysis included 208 immune-competent, non-pregnant, ART-naive HIV-
positive patients from Uganda with a ﬁrst episode of pulmonary TB. CD4+ T-cell counts were measured
using ﬂow cytometry. Age was deﬁned as 24, 25–29, 30–34, and 35–39 vs. 40 years. Nutritional status
was deﬁned as normal (>18.5 kg/m2) vs. underweight (18.5 kg/m2) using the body mass index (BMI).
Multivariate random effects linear mixed models were ﬁtted to estimate differences in CD4+ T-cell
recovery in relation to speciﬁed determinants.
Results: cART was associated with a monthly rise of 15.7 cells/ml (p < 0.001). Overall, age was not
associated with CD4+ T-cell recovery during TB therapy (p = 0.655). However, among patients on cART,
the age-associated CD4+ T-cell recovery rate varied by sex and nutritional status, such that age <40 vs.
40 years predicted superior absolute CD4+ T-cell recovery among females (p = 0.006) and among
patients with a BMI 18.5 kg/m2 (p < 0.001).
Conclusions: TB-infected HIV-positive patients aged 40 years have a slower rate of immune restoration
given cART, particularly if BMI is >18.5 kg/m2 or they are female. These patients may beneﬁt from
increased monitoring and nutritional support during cART.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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With expanded access to combination antiretroviral therapy
(cART) for people living with HIV (PLWH), the goal of HIV disease
management has shifted from delaying death to maintaining a
high quality of life. The effectiveness of cART in PLWH is directly
linked to its proven capacity to reverse HIV-associated immune
deﬁciency, as measured by the post-treatment rise in CD4+§ This work was presented at the 2014 American Society of Tropical Medicine and
Hygiene conference in New Orleans, Louisiana, USA.
* Corresponding author. Tel.: +1 706 542 5770.
E-mail address: aezeamam@uga.edu (A.E. Ezeamama).
http://dx.doi.org/10.1016/j.ijid.2015.04.008
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).T-cells.1 However, immune recovery is seldom complete for PLWH
on cART.2 The drivers of incomplete immune reconstitution under
cART are poorly elucidated. In general, immunity is impacted by
age, nutritional status, comorbid health conditions, and lifestyle
factors.
The impact of aging on immune function has been described.3
With advancing age, the thymus involutes, contributing to
reductions in the population of naı¨ve T-cells and a peripheral T-
cell receptor repertoire that is skewed towards memory T-cells.4
These functional changes in T-cell populations are compounded by
a reduced capacity for generating T-cell precursors to seed the
thymus and the production of fewer naı¨ve B-cells in the bone
marrow, a lower quality of naı¨ve T-cells produced from the thymus
of older individuals, less potent antibodies to foreign antigens, andciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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advancing age. Malnutrition is a driver of immune suppression and
dysregulation5 that may interact with age to interfere with
immune responsiveness. Micro- and macronutrient deﬁciencies
weaken the immune system partly through accelerated atrophy of
the thymic and lymphoid tissue, alteration of T-cell subsets, and
the cytokine response.6,7
Some epidemiological studies have associated older age at HIV
infection with faster progression to AIDS in the pre-ART era.8,9
However, the results of investigations on age-associated differ-
ences in the CD4+ T-cell response for HIV-infected adults on highly
active antiretroviral therapy (HAART) have been more variable in
the context of cART.10,11 Some studies have found evidence for a
slower rate of CD4+ T-cell recovery or lower magnitude of CD4+ T-
cell recovery in older compared to younger HIV-infected adults on
HAART.12–18 Others have found no age-related differences in CD4+
T-cell recovery following ART initiation,19–22 and at least one study
has reported a positive association between advanced age and
enhanced CD4+ T-cell recovery.23
In areas of high HIV prevalence, malnutrition and food-
insecurity overlap,5 even as those infected with HIV make the
same survival gains with cART described in resource-afﬂuent
settings.24 These nutritional and age-related immune dysregula-
tions may be both accelerated and magniﬁed in HIV-infected
populations due to HIV-related immune deﬁciency,25 age-related
decline in thymic output,26,27 and the high frequency of comorbid
conditions that further aggravate immune alterations.28 Yet, in
spite of the biologically plausible expectation that malnutrition
and advanced age in HIV-infected persons will unfavorably alter
the immune response to cART,29 there is limited empirical
evidence that this occurs in PLWH provided cART.
How immune recovery following cART initiation is impacted
by nutritional deﬁcits and advanced age at cART initiation in Sub-
Saharan Africa, where the burden of HIV lies, is unclear.30 CD4+
T-cell recovery in African PLWH may be materially different from
HIV-infected adults in developed countries due to a high
frequency of comorbid infections30–32 and malnutrition, and
lower overall quality of supportive clinical services. Of note, as
many as 33% of PLWH in resource-limited, high-HIV prevalence
Sub-Saharan Africa settings, have comorbid tuberculosis (TB)
disease.33 Concurrent TB and HIV upregulates immune activation
and inﬂammation, and complicates the diagnosis, presentation,
and clinical management of the respective diseases.34 A recent
study from South Africa suggested that the CD4+ T-cell recovery
rate is comparable for HIV-infected persons with and without
TB.35 However, the understanding of age-related differences in
immune recovery for HIV and TB co-infected persons is limited.
Therefore, the age-related differences in the rate of immune
recovery in HIV and TB co-infected adults observed during TB
treatment with or without cART were examined in the present
study. Secondarily, sex and nutritional status were examined as
candidate modiﬁers of age-associated changes in CD4+ T-cell
counts during TB therapy, to inform current understanding of
immune recovery in TB and HIV-infected adults on cART. It was
hypothesized that immune recovery following ART initiation will
decline with increasing age and may be contingent on nutritional
status.
2. Methods
2.1. Study design, parent study, and population
This study comprised a secondary analysis of differences in
CD4+ T-cell recovery rates among 13–60-year-old HIV and TB co-
infected patients during the time of pulmonary TB therapy, with or
without cART, in Kampala, Uganda. Details of the design andﬁndings of the parent study have been reported elsewhere.36
Brieﬂy, an open-label randomized trial of simultaneous cART and
TB treatment vs. immediate TB treatment with delayed cART until
clinically indicated per standard of care, was implemented
between October 2004 and October 2008. At the time, the standard
for TB care in HIV infection included immediate TB treatment with
ART initiated upon the development of an AIDS-deﬁning opportu-
nistic infection and/or when the absolute CD4+ T-cell count
dropped below 200 cells/ml. All participants were cART-naı¨ve, non-
pregnant, without a history of TB, free of a World Health
Organization (WHO) stage IV AIDS-deﬁning condition, and
immune competent (i.e. CD4+ T-cell count 350 cells/ml) at
enrollment. The present analysis included all patients with two or
more CD4 assessments (n = 208) within the 6 months of follow-up
from enrollment through the end of TB therapy.
2.2. Ethical approval
The protocol for the parent study was approved by the
institutional review boards of the University of Georgia, Case
Western Reserve University, University of California, San Francisco,
the Joint Clinical Research Center and the Uganda National Council
for Science and Technology. The sponsors of the parent study were
not involved in the design or implementation of the present
analysis, or in the interpretation of the results.
2.3. Follow-up, measurements, and variable deﬁnitions
At enrollment, standardized questionnaires were used to collect
socio-demographic and health data. Study participants were
evaluated monthly. Microscopic evaluation of TB disease clearance
was done for each patient as needed and for all, regardless of
indication, at months 0, 1, 2, and 5. HIV-1 RNA levels were
measured using the Roche Amplicor assay at months 0, 1, 2, and 5;
this assay has a minimum detection level of 400 copies/ml.
2.3.1. Primary outcome
The absolute CD4+ T-cell count was measured monthly via ﬂow
cytometry; this is the primary indicator of immune recovery.
Absolute CD4+ T-cell counts (in cells/ml) were evaluated as a linear
variable with the outcome matrix including all repeated measures
of CD4 for each patient given the observational study design.37
2.3.2. Determinants: cART, age, malnutrition
cART status was deﬁned on the basis of randomization to
concurrent cART vs. placebo during TB treatment. Baseline age was
deﬁned in categories of 24, 25–29, 30–34, 35–39, and 40 years,
and was used as an indicator of differences in thymus function at
cART initiation. Malnutrition was deﬁned as underweight (body
mass index (BMI) <18.5 kg/m2), or normal (BMI 18.5 kg/m2).
Viral load was deﬁned as a time-varying covariate using the lag of
log10-transformed RNA values. Time was deﬁned in months and
analyzed as a linear variable.
2.3.3. Confounders/modiﬁers
Baseline factors considered potential confounders in this study
included sex (male vs. female), employment (yes vs. no), smoking
(current, former vs. never), marital status (never married,
divorced/separated/widowed vs. married), and baseline functional
status deﬁned using the Karnofsky score (90 (i.e. able to function
normally with minor signs of disease) vs. <90 (i.e. lower functional
status)).
2.3.4. Statistical analyses
Multivariable random effects mixed linear regression models
were ﬁtted in SAS software version 9.2 (SAS Institute Inc.). An
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for non-independence of repeated CD4+ T-cell measurements
within individuals and accounted for potential within-subject
differences in the trajectory of CD4+ T-cell change over time by
including a random intercept for individual patients. Empirical
standard errors were used for all estimations to ensure that
signiﬁcance tests were robust to any misspeciﬁcation of the
covariance matrix.
An extensive array of potential confounders of the relation-
ship between age and change in CD4 values were considered. In
addition to speciﬁed potential confounders, adjustments were
made for cART status, malnutrition, viral load, and time. A lack of
information on any confounding covariate was addressed
analytically using the missing indicator method. The potential
for modiﬁcation in the association between age and change in
CD4 values during follow-up by patient sex and baseline
underweight status were examined. For this assessment,
differences in likelihood ratio tests between nested models
were used to determine the contribution of these factors –
included in multivariate models as three-way interactions
(agetimesex or agetimeunderweight) – to improvement
of the overall model ﬁt and hence the presence of signiﬁcant
heterogeneity.
3. Results
3.1. Sample characteristics
The parent study screened 253 HIV and TB co-infected patients
for inclusion. Of these, 45 were excluded from this secondary
analysis due to non-repeated CD4+ T-cell assessment and
inability to determine whether the patient was allocated
concurrent vs. non-concurrent cART in the parent study
(Figure 1). The analytic sample included 208 individuals, with
slightly more males (57%) than females, all with WHO HIV disease
stage 1 or 2 at baseline. The average participant was 31.8 years old
and the mean absolute CD4+ T-cell count at enrollment was
573 cells/ml. At enrollment, 23.6%, 26.9%, 21.2%, 16.8%, and 11.5%
of the sample were aged <25, 25–29, 30–34, 35–39, and 40
years. The majority of participants (64.7%) were employed, 27%Intervenon ar m
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Figure 1. Secondary analysis study of a randomized clinical trial on TB therapy only ver
infected participants in Kampala, Uganda, 2004–2008.were current drinkers, 11% self-identiﬁed as current smokers, and
40.8% had more than 7 years of education (Table 1). There were no
differences by age-group with respect to baseline health status
indicators including hemoglobin levels, CD4+ T-cell count, log
viral load, and BMI. However, the proportion of female patients
declined signiﬁcantly with increasing age category (Table 2). The
WHO HIV disease stage did not differ by age category at
enrollment (data not shown).
During the 6 months of TB therapy, the CD4+ T-cell count
increased by approximately 2 CD4+ T-cells each month. However,
among patients on TB therapy without cART, a net decline of
2.5 CD4+ T-cells per month was observed, whereas patients on
concomitant TB therapy and cART gained approximately 8 CD4+
T-cells each month in the overall group. Overall, and within
treatment strata, nutritional status was not independently
associated with CD4+ T-cell recovery, although underweight
patients gained more cells per month in comparison to patients of
normal weight at enrollment. Each log increment in HIV RNA viral
load was associated with a net deﬁcit in monthly absolute CD4+
T-cells recovered, but this association was not statistically
signiﬁcant overall or within strata of concurrent vs. delayed
cART. Over the study period, women on average gained more
CD4+ T-cells per month compared to men in the overall sample.
The magnitude and direction of sex-associated change in CD4+ T-
cells differed by cART status. Among study participants on
concurrent cART and TB treatment, women gained nearly 24 more
CD4+ T-cells per month compared to men. On the other hand,
among patients on TB treatment without cART, women in
comparison to men lost approximately 7 CD4+ cells/ml per
month (Table 3).
3.2. Effect of age, ART, and interactions with sex and BMI
In the entire sample, cART use during TB treatment was
associated with an average gain of 16 CD4+ T-cells per month.
Overall, the CD4+ T-cell recovery rate was higher for three of the
four younger age categories in comparison to patients aged 40
years, but these age-associated differences were not statistically
signiﬁcant. However, the magnitude and direction of age-
associated differences in immune recovery varied based onExcluded (n=9 )
Missing data on enrollm ent
allocaon
pa ents
0
≥2 CD 4
217)
ded at
sis
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Table 1
Baseline socio-demographic, immunologic, and health status of 208 HIV and
pulmonary tuberculosis co-infected Ugandans
Mean SD
Age, years 31.8 7.9
Baseline BMI, kg/m2 19.8 2.5
Viral load 127 708 195 021
Log viral load 4.53 0.87
Absolute CD4 cell count, cells/ml 572.3 243.4
CD4 percent 30.1 9.93
Absolute CD8 cell count, cells/ml 877 476
Hemoglobin, g/dl 12.1 1.8
Baseline alanine aminotransferase 31.4 22.3
CD4:CD8 ratio 0.8 0.5
n %
Randomized to HAART 103 49.5
Age categories, years
<25 49 23.6
25–29 56 26.9
30–34 44 21.2
35–39 35 16.8
40+ 24 11.5
Underweight (BMI 18.5 kg/m2) 69 33.2
Marital status
Single/never married 30 14.6
Currently married 98 47.6
Divorced/separated/widowed 78 37.8
Sex
Male 118 56.7
Female 90 43.3
Employed 134 64.7
Educational status
0–P5 education 57 30.1
P6–P7 education 55 29.1
S1–S3 education 36 18.9
S4–S6 education 42 21.8
Above secondary education 18 9.4
Behavioral risk factors
Current alcohol drinker 56 27.2
Smoking status
Never 146 70.2
Former 40 19.2
Current 22 10.6
Baseline health status
Abnormal indication on general physical
examination
130 62.5
Normal blood pressure 157 75.5
Karnofsky score 90 83 39.9
Presence of a comorbid diagnosis 82 40.0
HIV WHO stage
1 4 2.1
2 188 97.9
SD, standard deviation; BMI, body mass index; HAART, highly active antiretroviral
therapy; WHO, World Health Organization.
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test of differences in nested models with and without the
agetimeART interaction; data not shown). Similarly, stratiﬁca-
tion by cART identiﬁed a marginally signiﬁcant qualitative age-
associated interaction in CD4+ T-cell recovery (Table 3,
agetimeART interaction; p-value = 0.058). Among patients onTable 2
Baseline description of HIV and pulmonary tuberculosis co-infected study participants
<25 years
n = 49
25–29 years
n = 56
Absolute CD4+ T-cell, mean (SD) 572 (250) 558 (248) 
BMI, mean (SD) 19.9 (2.7) 20.0 (2.7) 
Log viral load, mean (SD) 4.39 (0.85) 4.58 (0.85) 
Female, n (%) 29 (59.2) 33 (58.9) 
cART, n (%) 24 (49.0) 32 (57.1) 
Hemoglobin, g/dl, mean (SD) 11.7 (1.7) 11.9 (1.6) 
SD, standard deviation; BMI, body mass index; cART, combination antiretroviral therap
a p-Values are based on the t-test of difference in means for continuous variables anconcurrent cART and TB therapy, the absolute CD4+ T-cell count
increased from enrollment through the end of 6 months of TB
therapy by an average value of 8 CD4+ T-cells/ml per month, and
patients in the younger age strata all gained more CD4+ T-cells
than those 40 years. The magnitude of CD4+ T-cells recovered in
patients on cART and TB treatment increased with younger age at
enrollment. Conversely HIV-infected patients on TB therapy alone
lost an average of 2.5 CD4+ T-cells/ml monthly, and the age-
associated change in CD4 values was variable with a slower rate of
recovery noted for only one of the four younger categories vs. the
oldest age category.
The age-associated rate of immune recovery during the
6 months of TB treatment was dependent on baseline nutritional
status (p-value agetimeBMI: <0.0358) and sex (p-value
agetimesex: <0.0001) among patients on concurrent TB and
cART. Speciﬁcally, a faster rate of CD4+ T-cell count recovery was
noted for patients in the four younger age strata compared to the
oldest age category among female patients and among normally
nourished patients at enrollment. As in the overall sample, the
magnitude of CD4+ T-cells recovered during TB therapy was
inversely proportional to patient age at enrollment. Conversely, the
association between age and CD4+ T-cell recovery was variable and
non-signiﬁcant for male patients and for patients underweight at
enrollment (Table 4).
4. Discussion
In this sample of immune-competent TB and HIV co-infected
adult men and women followed through the end of anti-TB therapy
with or without cART, an age-associated differential rise in CD4
values during 6 months of TB therapy was found among patients
on concurrent anti-TB and cART, but not in patients on TB
treatment without cART. For patients on simultaneous TB and ART
therapies, the average monthly CD4+ T-cell gain was inversely
proportional to age at enrollment. This inverse association
between age at enrollment and the absolute number of CD4+ T-
cells recovered was particularly strong and statistically signiﬁcant
among female HIV and TB co-infected adults whose BMI was
18.5 kg/m2 at enrollment.
In line with the study hypothesis, age 40 years at ART
initiation was associated with a sub-optimal immune recovery rate
relative to younger age-groups. The results of the present study
conﬁrm the age-related sub-optimal immune recovery observed in
adult HIV-infected patients from West Africa and South Africa,35,38
as well as similar ﬁndings in several developed country
settings.14,16–18 None of these prior studies investigated HIV and
TB co-infected patients. Thus our results corroborate these
previous reports and suggest that co-infection with TB may not
alter the age-associated absolute CD4+ T-cell recovery deﬁcits
reported previously.
These data conﬁrm the previously reported age-associated
immune recovery deﬁcits in mostly immune-compromised HIV-
infected adults and extend this observation to immune-competent by age at enrollment
30–34 years
n = 44
35–39 years
n = 35
40+ years
n = 24
p-Valuea
627 (251) 561 (243) 524 (206) 0.6854
19.6 (2.5) 19.7 (2.0) 20 (2.8) 0.8077
4.64 (0.85) 4.64 (0.79) 4.36 (1.1) 0.6671
14 (31.8) 9 (25.7) 5 (20.8) <0.0001
20 (45.5) 17 (48.6) 10 (42.7) 0.4088
12.3 (1.8) 12.4 (1.7) 11.7 (2.1) 0.3479
y.
d the Chi-square test of difference in proportions for categorical variables.
Table 3
Monthly change in absolute CD4 cell count among HIV and tuberculosis co-infected Ugandan adults during 6 months of tuberculosis treatment in relation to age, concurrent
cART, sex, nutritional status, time, and viral loada
Entire sample (n = 208)b TB therapy only, no ART (n = 105) Concurrent ART and TB therapy (n = 103)
Risk difference (95% CI) Risk difference (95% CI) Risk difference (95% CI)
Time (per month increment) 1.87 (6.7, 10.5) 2.5 (11.2, 6.1) 8.2 (5.0, 21.5)
BMI <18.5 vs. 18.5 kg/m2 8.3 (5.0, 27.0) 8.7 (10.8, 28.1) 3.9 (12.6, 20.4)
Female vs. male sex 10.7 (3.72, 23.9) 3.32 (21.5, 15.0) 23.7 (3.0, 50.4)
Viral load (per log10 increment) 3.54 (7.7, 0.6) 3.3 (8.2, 1.6) 2.0 (7.2, 3.2)
Punctuated ART vs. standard of care 16.3 (4.8, 27.8) N/A N/A
Age categories, years p-Value agetime: 0.362 p-Value agetime: 0.495 p-Value agetime: 0.378
<25 16.1 (2.18, 34.4) 2.9 (23.9, 18.0) 33.2 (4.25, 62.2)
25–29 12.4 (3.3, 28.0) 1.8 (20.7, 17.1) 21.8 (1.0, 44.6)
30–34 12.7 (3.8, 29.3) 9.2 (11.8, 30.2) 4.34 (19.2, 27.9)
35–39 5.3 (27.1, 16.5) 21.7 (51.0, 7.7) 4.91 (36.5, 46.3)
40+ Ref. Ref. Ref.
When the p-value associated difference
in likelihood ratio test between nested
models was <0.05, stratiﬁcation was
done by levels of the effect modiﬁer
Interaction: agetimeART; p-value = 0.0575
cART, combination antiretroviral therapy; TB, tuberculosis; ART, antiretroviral therapy; CI, conﬁdence interval; BMI, body mass index; N/A, not applicable.
a All effects were estimated from mixed general linear models using PROC Mixed in SAS version 9.2. Risk differences represent the average monthly change in absolute CD4
values in relation to shown predictors. Age effects were derived from the following model: [CD4it] = a + b1time + b2age + b3timeage + b4sex + b5baseline underweight
status + b6lag viral load + b7marital status + b8employment + b9smoking status. The BMI effect was derived from the following model: [CD4it] = a + b1time + b2baseline
underweight status + b3timebaseline underweight status + b4sex + b5age +b6lag viral load + b7marital status + b8employment + b9smoking status.
b The sample size in each column is based on unique individuals included in multivariate analyses; numbers within age strata are derived from the baseline ﬁle.
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difference in CD4+ T-cell count at enrollment, thus excluding
the presence of lower CD4+ T-cell counts in older persons with HIV
at the beginning of cART as an alternative explanation for this
ﬁnding. The pattern of association observed is in line with previous
reports that the CD4+ T-cell immune recovery rate given cART may
be more effective in younger PLWH, in part due to relatively more
preserved thymic function.14
The study ﬁnding of signiﬁcant age-related differences in
immune recovery is not corroborated by investigations among
HIV-infected adults from Uganda30,31 and Barbados.39 Important
methodological differences were noted between these latter
studies and the present study that may in part explain this
inferential divergence. The present study included HIV and TB co-
infected adults and was adjusted for major known confounders/
modiﬁers of immune function including nutritional status and
several socio-demographic factors. Further, coincident TB infection
was controlled for by design, allowing the derivation of more
thoroughly adjusted estimates of effect compared to the previous
reports.30,31
Neither sex nor nutritional status was an independent predictor
of overall immune recovery in this study. However, both factors
modiﬁed the age-associated differentials in immune recovery rate.
The observation of age-related differences in immune recovery
among nutritionally adequate but not underweight adults at ART
initiation is noteworthy and suggests that any age-related immuneTable 4
Nutritional status- and sex-dependent age-related monthly increases in absolute CD4
therapy during 6 months of tuberculosis treatment in Kampala, Ugandaa
Baseline nutritional status 
BMI <18.5 kg/m2 (n = 36) BMI 18.5 kg/m
Risk difference (95% CI) Risk difference 
Age categories, years Agetime: p = 0.954 Agetime: p <0
<25 1.5 (30.9, 28.0) 56.0 (22.8, 83.4
25–29 17.3 (16.6, 49.2) 50.2 (21.0, 73.2
30–34 0.1 (41.1, 41.2) 36.7 (8.2, 57.2) 
35–39 14.6 (21.6, 50.8) 30.1 (0.3, 60.4
40+ Ref. Ref. 
p-Value agetimeBMI: 0.036 
a Estimates were derived from linear mixed models implemented via SAS PROC Mi
measures of CD4 values. All estimates are adjusted for time, patient sex, and lag viral recovery advantage conferred by preserved thymic function in
younger HIV-infected adults is over-ridden by immune dysregula-
tion due to nutritional impairment. The signiﬁcance of stronger
age-related deﬁcits in immune recovery among women is less clear
and warrants further elucidation in future studies. Female sex may
be a surrogate indicator of greater compliance or generally better
health-seeking behavior or health status at cART initiation, which
impacts favorably on the immune recovery rate during TB therapy.
Several African studies have associated female sex with a greater
magnitude of immune recovery and greater overall adherence to
ART,40,41 suggesting that sex differentials in adherence to cART
may be important.
In the present study, however, adherence to both TB and ART
was similarly high for men and women because all were given
directly observed therapy, but underweight status was more
prevalent in men than women at enrollment. This study group has
previously reported sex differences in adiposity, TB-associated
lean tissue wasting, and relationships to mortality among Ugandan
adults.42 The relative contribution of sex-related differences in
metabolic dysregulation and of sex-related behavioral differences
such as adherence driving the observed age-related differentials in
CD4+ T-cell recovery deserves further elucidation in future studies
to inform effective intervention strategies.
This study is subject to important limitations that should lead to
cautious interpretation of the ﬁndings. First, the observational
design of this study limits the ability to conclude that advanced age counts in tuberculosis and HIV co-infected patients on concurrent antiretroviral
Sex
2 (n = 67) Female (n = 50) Male (n = 53)
(95% CI) Risk difference (95% CI) Risk difference (95% CI)
.001 Agetime: p = 0.006 Agetime: p = 0.795
) 52.8 (18.7, 86.9) 14.6 (15.6, 44.7)
) 53.7 (25.8, 81.4) 5.2 (19.6, 30.0)
47.0 (11.6, 82.4) 6.5 (19.0, 32.1)
) 26.5 (21.7, 74.8) 0.2 (32.3, 31.9)
Ref. Ref.
p -Value agetimesex: <0.001
xed. The model assumes an unstructured covariance for within-subject repeated
load.
A.E. Ezeamama et al. / International Journal of Infectious Diseases 35 (2015) 73–7978at enrollment leads to poor immune recovery. Second, this analysis
included a small sample of HIV and TB co-infected patients on
concurrent ART and TB therapy. Consequently between 10 and
32 patients were in the ﬁve age-strata speciﬁed. Third, the
signiﬁcant association between advanced age and lower immune
recovery rate noted in this study was evident in sub-group
analyses. However, given smaller sample sizes in sub-group
analyses, one would have expected less power to detect signiﬁcant
associations; this did not materialize in this study. Future studies
are needed from resource-limited settings, with careful consider-
ation of nutritional status and patient socio-demographic factors,
to conﬁrm or refute these ﬁndings. The strengths of this study
include the rigorous control for important confounders, evaluation
of effect modiﬁcation, and the use of a sample of HIV and TB
infected adults that allowed the simultaneous contrasting of the
differential impact of age on immune responses in the context of
TB treatment alone versus concomitant TB and ART.
In conclusion, it was found that given cART, the recovery of
CD4+ T-cells was age-dependent and that younger patients
recovered their CD4+ T-cells at a higher rate than their older
counterparts. Moreover, the rate of immune recovery was affected
by gender and nutritional status. These ﬁndings suggest that age,
sex, and nutritional status may be important determinants of
health outcomes in HIV and TB co-infected adults. As a result,
therapeutic approaches may need to be tailored in accordance with
these factors. The data from this study suggest that increased
monitoring and nutritional support as adjunct therapy should be
considered for HIV-positive patients with TB and that those
starting cART at an older age may beneﬁt from this intervention.
The mitigation of malnutrition in TB and HIV co-infected patients,
which is a modiﬁable risk factor, may enhance immune recovery in
adult PLWH on cART.
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